Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 17, 2026

Earnings live: Palo Alto Networks stock sinks after company cuts full-year-forecast

View original at finance.yahoo.com
Earnings live: Palo Alto Networks stock sinks after company cuts full-year-forecast The software trade is still under pressure. Late Tuesday, shares of cybersecurity giant Palo Alto Networks (PANW) fell as much as 6% after the company cut its full-year earnings outlook…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Coinbase has seen $420 million of transaction revenue in Q1 through February 10

    80% confidence
  • 74% of S&P 500 companies had reported results as of Feb. 13, with blended earnings growth at 13.2% for Q4

    80% confidence
  • Airbnb forecasts Q1 revenue between $2.59 billion and $2.63 billion, ahead of analyst estimates of $2.52 billion

    80% confidence
  • Applied Materials stock is up 27% year to date in 2026

    80% confidence
  • Walmart's Q4 report will be the first under new CEO John Furner and the first since the company joined the trillion-dollar market cap club

    80% confidence
  • If 13.2% blended earnings growth holds, it would represent the 10th consecutive quarter of annual earnings growth and fifth consecutive quarter of double-digit growth for the S&P 500

    80% confidence
  • Crocs issued full-year 2026 profit guidance of $12.88 to $13.35 per share, beating analyst estimates of $11.92

    80% confidence
  • McDonald's Extra Value Meal is fundamental in the current operating environment and many locations would keep it

    80% confidence
  • McDonald's is factoring in changing diet preferences such as customers opting for less sugary drinks into its test offerings

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com